News

Conference Insider

Experts Investigate Value of Chromosomal Complexity in Imatinib Treatment for High-Risk GIST

06/17/2021

Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting.

Investigators sought to...

06/17/2021

Oncology

Conference Insider

Pimitespib Significantly Improves PFS, OS in Patients with Advanced GIST

06/15/2021

A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.

A phase III trial evaluated the...

06/15/2021

Oncology

News

Ripretinib Shows Promise In Patients with Refractory Advanced GIST

03/24/2021

Results of a phase 1 trial indicate ripretinib may be a beneficial treatment option for patients with refractory advanced GIST.

Results of a phase 1 trial...

03/24/2021

Oncology

News

Prolonged Adjuvant Imatinib Therapy Tied to Extended OS in High-Risk GIST

02/10/2021

Prolonged adjuvant imatinib for high-risk GIST led to a superior OS over shorter-term imatinib treatment, according to a trial comparing 3- and 1-year regimens.

Prolonged adjuvant imatinib for...

02/10/2021

Oncology

News

Investigational MKIs Improve Outcomes in Metastatic GIST

01/25/2021

Using first-line multi-kinase inhibitors (MKIs) aside from imatinib did not lead to early resistance or decreased efficacy of second-line therapy for metastatic GIST.

Using first-line multi-kinase...

01/25/2021

Oncology

News

Clinical Differences May Exist in Multiple vs Single GISTs

01/21/2021

A retrospective analysis suggests that the clinical features and treatment approaches for multiple GISTs may differ from single GISTs, presenting a gap in the treatment landscape.

A retrospective analysis...

01/21/2021

Oncology

News

Axitinib Plus Octreotide Acetate Safe, Active for Grade 1/2 Gastric NETs

01/19/2021

Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.

Axitinib in combination with...

01/19/2021

Oncology

News

Surgery Plus Systemic Therapy Improves Outcomes in Stage IV GIST

01/14/2021

A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.

A study evaluating treatment...

01/14/2021

Oncology

News

Follow-Up INVICTUS Trial Data Show Improved OS With Ripretinib for GIST

10/16/2020

OS improved for patients with advanced GIST treated with ripretinib, according to follow-up study findings presented at the 2020 Virtual ESMO Annual Meeting.

OS improved for patients with...

10/16/2020

Oncology

News

Microscopically Positive Resection Margin Has No Influence on OS, RFS in GIST

09/14/2020

R1 margins did not significantly influence OS and RFS after resection compared with R0 margins in patients with GIST, according to results from a retrospective study.

R1 margins did not significantly...

09/14/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology